These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8574641)

  • 21. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).
    Leonardi ET; Azmitia EC
    Neuropsychopharmacology; 1994 Jul; 10(4):231-8. PubMed ID: 7945733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
    Callaghan PD; Irvine RJ; Daws LC
    Neurochem Int; 2005 Oct; 47(5):350-61. PubMed ID: 15979209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro.
    Gobbi M; Moia M; Pirona L; Ceglia I; Reyes-Parada M; Scorza C; Mennini T
    J Neurochem; 2002 Sep; 82(6):1435-43. PubMed ID: 12354291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.
    Huether G; Zhou D; Rüther E
    J Neural Transm (Vienna); 1997; 104(8-9):771-94. PubMed ID: 9451711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain.
    Kirilly E
    Neuropsychopharmacol Hung; 2010 Sep; 12(3):413-23. PubMed ID: 20962361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
    Wang X; Baumann MH; Xu H; Rothman RB
    Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
    Hekmatpanah CR; Peroutka SJ
    Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
    Hewton R; Salem A; Irvine RJ
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines.
    Xie T; Tong L; McLane MW; Hatzidimitriou G; Yuan J; McCann U; Ricaurte G
    Neuropsychopharmacology; 2006 Dec; 31(12):2639-51. PubMed ID: 16452989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse.
    Kramer K; Azmitia EC; Whitaker-Azmitia PM
    Brain Res Dev Brain Res; 1994 Mar; 78(1):142-6. PubMed ID: 7911745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo.
    Gartside SE; McQuade R; Sharp T
    J Pharmacol Exp Ther; 1996 Oct; 279(1):277-83. PubMed ID: 8859004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
    Bankson MG; Cunningham KA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.
    Schuldiner S; Steiner-Mordoch S; Yelin R; Wall SC; Rudnick G
    Mol Pharmacol; 1993 Dec; 44(6):1227-31. PubMed ID: 7903417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.
    Zolkowska D; Rothman RB; Baumann MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):604-10. PubMed ID: 16644904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.
    Giannaccini G; Betti L; Pirone A; Palego L; Fabiani O; Fabbrini L; Mascia G; Giusti L; Macchia M; Giusiani M; Martini C; Lucacchini A
    Neurochem Int; 2007 Dec; 51(8):496-506. PubMed ID: 17602794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.
    Bowyer JF; Young JF; Slikker W; Itzak Y; Mayorga AJ; Newport GD; Ali SF; Frederick DL; Paule MG
    Neurotoxicology; 2003 Jun; 24(3):379-90. PubMed ID: 12782103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').
    Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
    Neuropsychopharmacology; 2005 Mar; 30(3):550-60. PubMed ID: 15496938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
    Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC
    J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice.
    Achat-Mendes C; Ali SF; Itzhak Y
    Neuropsychopharmacology; 2005 Jun; 30(6):1128-37. PubMed ID: 15688084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.